Abstract 4403
Background
The B-cell receptor (BCR) signaling pathway plays a central role in non-Hodgkin lymphoma (NHL). Despite available agents targeting the BCR pathway, there continues to be a need for alternative therapies in the relapsed/refractory (R/R) setting due to agent-specific toxicities and differences in efficacy among agents and lymphoma subtypes. HMPL-689 is a highly selective small molecule inhibitor of phosphoinositide 3-kinase-delta (PI3Kδ), one of the key signaling molecules in BCR function. HMPL-689 has shown strong dose- and time-dependent inhibition of B-cell activation in rats. There is one ongoing clinical study in China, as well as the current study, which is being conducted in the United States (US) and European Union (EU). We present here a trial-in-progress description of this US/EU study, a phase 1 trial with a dose-escalation stage (ESC) and a dose expansion stage (EXP).
Trial design
Study Population: The target population is patients (pts) with histologically confirmed R/R NHL, including chronic lymphocytic leukemia, small lymphocytic lymphoma, mantle cell lymphoma, follicular lymphoma, marginal zone lymphoma, or Waldenström’s macroglobulinemia/ lymphoplasmacytic lymphoma. In the ESC, patients must have exhausted all available approved therapy options. In the EXP, patients must be naïve to PI3K inhibitors. Objectives: The primary objective is to assess the safety and tolerability of HMPL-689 in pts with R/R NHL and to determine the maximum-tolerated dose (MTD) and the recommended phase 2 dose (RP2D). Preliminary efficacy will be evaluated in the dose expansion stage. Study Design: Dose-escalation will follow a modified toxicity probability interval scheme-2 and enroll 6 to 30 pts, until the MTD or the maximum sample size is reached. The proposed doses are 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, and 50 mg oral, once daily in 28-day cycles. HMPL-689 will be administered until disease progression, intolerable toxicity, no further benefit from study treatment, withdrawal, end of study, or death. The EXP will further evaluate the MTD/RP2D in ∼50 pts, with ∼10 pts each, in subtype-specific cohorts.
Clinical trial identification
NCT03786926.
Editorial acknowledgement
Hoang-Lan Nguyen, PhD, Hutchison MediPharma (US), Inc.
Legal entity responsible for the study
Hutchison MediPharma, Limited.
Funding
Hutchison MediPharma, Limited.
Disclosure
J. Cohen: Advisory / Consultancy: Seattle Genetics; Advisory / Consultancy: Janssen; Advisory / Consultancy: Kite/Gilead; Research grant / Funding (institution): Bristol-Myers Squibb; Research grant / Funding (institution): Novartis; Research grant / Funding (institution): LAM Therapeutics; Research grant / Funding (institution): Takeda; Research grant / Funding (institution): Genentech; Research grant / Funding (institution): LRF; Research grant / Funding (institution): ASH; Research grant / Funding (institution): UNUM; Research grant / Funding (institution): BioInvent; Research grant / Funding (institution): AstraZeneca. R. Cordoba Mascunano: Advisory / Consultancy, Travel / Accommodation / Expenses: AbbVie; Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Celgene; Advisory / Consultancy, Speaker Bureau / Expert testimony: Gilead; Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Janssen; Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Roche; Advisory / Consultancy: Takeda; Advisory / Consultancy, Speaker Bureau / Expert testimony: Servier; Speaker Bureau / Expert testimony: Bristol-Myers Squibb. A.J.M. Ferreri: Advisory / Consultancy, Travel / Accommodation / Expenses: Gilead; Advisory / Consultancy, Speaker Bureau / Expert testimony: Kite; Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Celgene; Research grant / Funding (institution), Travel / Accommodation / Expenses: Roche Pharma AG. C. Yang: Shareholder / Stockholder / Stock options, Full / Part-time employment: Hutchison MediPharma Ltd. M. Kania: Shareholder / Stockholder / Stock options, Full / Part-time employment: Hutchison MediPharma Ltd. J. Kauh: Shareholder / Stockholder / Stock options, Full / Part-time employment: Hutchison MediPharma Ltd. N. Ghosh: Advisory / Consultancy, Speaker Bureau / Expert testimony: Seattle Genetics; Advisory / Consultancy, Speaker Bureau / Expert testimony: Pharmacyclics; Advisory / Consultancy, Speaker Bureau / Expert testimony: Janssen; Advisory / Consultancy, Speaker Bureau / Expert testimony: Gilead/Kite; Advisory / Consultancy, Speaker Bureau / Expert testimony: AbbVie; Speaker Bureau / Expert testimony: Bristol-Myers Squibb; Advisory / Consultancy: TG Therapeutics; Advisory / Consultancy: Celgene/Juno.
Resources from the same session
3620 - Safety, efficacy, PK and PD biomarker results of the first-in-human study of mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor BAY 1436032 in patients (pts) with mIDH1 advanced solid tumours
Presenter: Wolfgang Wick
Session: Poster Display session 1
Resources:
Abstract
5465 - Proof of concept clinical study by US-guided intratumor injection of VCN-01, an oncolytic adenovirus expressing hyaluronidase in patients with pancreatic cancer
Presenter: Manuel Hidalgo
Session: Poster Display session 1
Resources:
Abstract
2555 - A Phase 1a/b first-in-human, open-label, dose-escalation, safety, PK and PD study of TP-0903 in solid tumors
Presenter: John Sarantopoulos
Session: Poster Display session 1
Resources:
Abstract
3533 - First in human phase 1/2a study of PEN-866, a Heat Shock Protein 90 (HSP90) ligand – SN38 conjugate for patients with advanced solid tumors: Phase 1 results
Presenter: Johanna Bendell
Session: Poster Display session 1
Resources:
Abstract
4114 - A Phase I Open-Label, Non-Randomized Study of Recombinant Super-Compound Interferon (rSIFN-co) In Patients with Advanced Solid Tumors
Presenter: Amanda Seet
Session: Poster Display session 1
Resources:
Abstract
2537 - Evaluation of Pharmacodynamic (PD) Biomarkers in Advanced Cancer Patients Treated with Oxidative Phosphorylation (OXPHOS) Inhibitor, OPC-317 (OPC)
Presenter: Jie Qing Eu
Session: Poster Display session 1
Resources:
Abstract
5764 - Pharmacokinetic (PK) assessment of BT1718: A phase 1/2a study of BT1718, a first in class Bicycle Toxin Conjugate (BTC), in patients (pts) with advanced solid tumours
Presenter: Natalie Cook
Session: Poster Display session 1
Resources:
Abstract
2683 - A phase I open label dose escalation trial evaluating VT1021 in patients with advanced solid tumors.
Presenter: Wael Harb
Session: Poster Display session 1
Resources:
Abstract
3609 - Interim Results from Trial of SL-801, a Novel XPO-1 Inhibitor, in Patients with Advanced Solid Tumors
Presenter: Judy Wang
Session: Poster Display session 1
Resources:
Abstract
3485 - Phase 1 Trial of Fruquintinib in Patients with Advanced Solid Tumors: Results of the Dose Escalation Phase
Presenter: Andrea Wang-Gillam
Session: Poster Display session 1
Resources:
Abstract